Skip to main content

Month: March 2025

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases. The combined company will have a significantly strengthened financial position to support a highly differentiated...

Continue reading

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases. The combined company will have a significantly strengthened financial position to support a highly differentiated and diverse pipeline...

Continue reading

Primech AI Launches Global Robotics as a Service (RaaS) Initiative with Chinachem Group Partnership

                                                                                    Pioneering AI-Powered Cleaning Technology Deployment Marks Strategic Expansion into Hong Kong Market SINGAPORE, March 04, 2025 (GLOBE NEWSWIRE) — Primech AI Pte. Ltd. (“Primech AI”) or (the “Company”), a subsidiary of Primech Holdings Limited (Nasdaq: PMEC), is proud to announce the launch of its innovative Robotics as a Service (RaaS) business line, revolutionizing the cleaning solutions industry. This strategic initiative addresses critical industry challenges including labor shortages, hygiene standards, and operational costs through proprietary AI-driven technology. As part of this global expansion strategy, Primech AI has signed a Memorandum of Understanding (MoU) with CCG Property Services, a subsidiary of Hong Kong’s leading...

Continue reading

Montero Receives Final Instalment of US$7 million from Tanzania

TORONTO, March 04, 2025 (GLOBE NEWSWIRE) — Montero Mining and Exploration Ltd. (TSX-V: MON) (“Montero” or the “Company”) is pleased to confirm that US$7,000,000 in cash (the “Final Instalment”) have been received by the Company from the United Republic of Tanzania (“Tanzania”). This payment represents the final instalment of the US$27,000,000 settlement between the Company and Tanzania and is expected to put an end to the dispute in connection with Tanzania’s expropriation of Montero’s Wigu Hill rare earth element project before the International Centre for Settlement of Investments Disputes (“ICSID”). The final net proceeds to be received by the Company is not certain at this time as final legal costs and other expenses Montero incurred in connection with defence and settlement of the Expropriation will now be determined as the...

Continue reading

Form 8.3 – Warehouse REIT Plc

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Warehouse REIT Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

MIND CTI Reports Fourth Quarter and Full Year 2024 Results

* Board Declares Cash Dividend* MIND CTI to Host Annual Meeting of Shareholders YOQNEAM, Israel, March 04, 2025 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications (UC) analytics and call accounting solutions for enterprises as well as enterprise messaging solutions, today announced results for its fourth quarter of 2024 and its full year ended December 31, 2024. The following will summarize our business in the fourth quarter of 2024 and provide a more detailed review of the financial results for the quarter and for the full year. Full financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial...

Continue reading

L.B. Foster Company Ends 2024 with Continuing Profitability Growth and Strong Cash Flow; Approves New, 3-Year $40 million Stock Repurchase Plan

Fourth quarter and full year 2024 gross margins improved 100 and 160 basis points while net sales were down 5.0% and 2.4%, respectively, highlighting improved portfolio profitability year over year. Fourth quarter net loss of $0.3 million was favorable $0.2 million versus last year; adjusted EBITDA1 of $7.2 million was favorable $1.1 million, or 18.7%, over the prior year quarter. Full year 2024 cash flow from operations was $22.6 million, with $24.3 million generated in the fourth quarter; Total debt declined $21.6 million during the quarter to $46.9 million; Gross Leverage Ratio1 of 1.2x decreased 0.7x during the quarter and 0.5x compared to last year. The Company’s Board of Directors authorized a new, 3-year $40 million stock repurchase program. The Company announced full year financial guidance for 2025 with net sales expected...

Continue reading

Village Super Market, Inc. Reports Results for the Second Quarter Ended January 25, 2025

SPRINGFIELD, N.J., March 04, 2025 (GLOBE NEWSWIRE) — Village Super Market, Inc. (NSD-VLGEA) today reported its results of operations for the second quarter ended January 25, 2025. Second Quarter HighlightsNet income of $16.9 million, an increase of 17% compared to the second quarter of the prior year Sales increased 4.2% and same store sales increased 2.3% Same store digital sales increased 9%Year-To-Date Fiscal 2025 HighlightsNet income of $29.7 million, an increase of 14% compared to $26.1 million in the prior year-to-date period Sales increased 4.1% and same store sales increased 2.4% Same store digital sales increased 8%Second Quarter of Fiscal 2025 Results Sales were $599.7 million in the 13 weeks ended January 25, 2025 compared to $575.6 million in the 13 weeks ended January 27, 2024. Sales increased due to an increase...

Continue reading

REPEAT: KP Tissue to Release its Financial Results and those of Kruger Products Inc. for the Fourth Quarter of 2024

MISSISSAUGA, Ontario, March 04, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX:KPT), which holds an interest in Kruger Products Inc., will release the financial results for KPT and Kruger Products Inc. for the fourth quarter of 2024 on Wednesday, March 5, 2025 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time. Conference Call InformationVia telephone: 1-888-699-1199 or 416-945-7677Via internet: www.kptissueinc.com Presentation material referenced during the conference call will be available at www.kptissueinc.com. Conference Call RebroadcastA rebroadcast of the conference call will be available until midnight, March 12, 2025 by dialing 1-888-660-6345 or 289-819-1450 and entering passcode 54225. The replay of the webcast will remain available on the website until midnight, March...

Continue reading

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key HighlightsSuccessful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron.Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership discussions.FDA confirmation of proposed 505(b)(2) bridging strategy leveraging the results from AD04-103—a relative bioavailability food-effect study—along...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.